1414P - Possible prognostic value of local immunity cellular factors in primary and recurrent soft tissue sarcomas

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Soft Tissue Sarcomas
Cancer Immunology and Immunotherapy
Presenter Elena Zlatnik
Citation Annals of Oncology (2016) 27 (6): 483-492. 10.1093/annonc/mdw388
Authors E. Zlatnik1, O. Kit2, I. Novikova1, T. Aliev3, E. Nepomnyashchaya1, T. Ausheva4, O. Selyutina1, I. Dashkova3, L. Vashchenko3, E. Andreyko3, E. Kechedzhieva3, I. Sidorenko3, E. Velieva3, L. Vladimirova5
  • 1Laboratory Of Immunophenotyping Of Tumors, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU
  • 2Surgical Department, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU
  • 3Department Of Soft Tissue Tumors, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU
  • 4Department Of Soft Tissue Tumors, Rostov Research Institute of Oncology, Rostov on Don/RU
  • 5Department Of Chemotherapy, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU

Abstract

Background

The purpose of the study was to analyze prognostic value of some cellular factors of immunologic microenvironment in soft tissue sarcomas (STS) for the development of an effective response to treatment for primary and recurrent tumors.

Methods

24 patients (13 women and 11 men aged 35 years and older) with primary (12) and recurrent (12) soft tissue sarcomas (G1-G4T2BN0M0, mostly poorly differentiated G3 tumors) underwent surgical removal of tumors with the following adjuvant chemotherapy and radiotherapy. Tissues of tumors and peritumoral area obtained during the surgery were homogenized; percentage of lymphocytes (T-, B-, NK, NKT, DP, DN, T-regs) was determined using FACSCantoII (BD) flow cytometer.

Results

Patients were divided into 4 groups according to the results of clinical observation: group A – primary tumors, marked treatment effect; group B – primary tumors, no treatment effect; group C – recurrent tumors, marked treatment effect; and group D - recurrent tumors, no treatment effect. Retrospective assessment of local immunity statuses of patients revealed a number of differences in lymphocyte content. Patients with primary STS showed significant prognostic value of CD16/56+ level in tumor tissue: 12.2 ± 1.6% in marked treatment effect and 6.1 ± 1.2% without an effect (p 

Conclusions

A high local level of DN-lymphocytes, especially in recurrent tumors, and decreased content of NK-cells in primary tumors can be considered as prognostic factors for effectiveness of treatment for soft tissue sarcomas.

Clinical trial identification

Legal entity responsible for the study

Rostov Research Institute of Oncology

Funding

Ministry of Health of the Russian Federation

Disclosure

All authors have declared no conflicts of interest.